| dc.description.abstract | The present study was designed to determine changes in spermatogenesis in adult mice after an intraperitoneal injection of vincristine. The effect of a GnRH antagonist synchronous to chemotherapy, which might protect spermatogenesis by halting cell division in spermatogenic cells, was also investigated. Method and Materials: A total of 30 adult male mice were studied in three equal groups of ten. In the V group, a single dose of the chemotherapy drug vincristine was injected intraperitonally at 1.5 mg/kg. In the V+C, group, the injection of Cetrorelix was started, and one week before to one week after vincristine injection continued ( for 3 weeks). Controls received no treatment. Samples were taken from the testicles, and fixed in Boueins fixative for light microscopy. Results: Comparing the mean number of Sertoli and spermatogony cells and the rate of spermatogenesis index (SI) in the V group with controls showed significant differences,which were not evident in the V+C group. Conclusion: According to the results, the cetrorelix antagonist (GnRH) could largely prevent side effects of vincristine administration regarding seminiferous tubules. é Asian Pacific Journal of Cancer Prevention, 2017. | |
